Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Position Reduced by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,552 shares of the medical equipment provider’s stock after selling 1,267 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Lantheus were worth $586,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in LNTH. Mercer Global Advisors Inc. ADV bought a new stake in Lantheus during the second quarter valued at $209,000. Mackenzie Financial Corp boosted its holdings in shares of Lantheus by 259.2% in the 2nd quarter. Mackenzie Financial Corp now owns 15,571 shares of the medical equipment provider’s stock valued at $1,250,000 after buying an additional 11,236 shares during the period. Creative Planning grew its position in shares of Lantheus by 48.5% during the 2nd quarter. Creative Planning now owns 23,714 shares of the medical equipment provider’s stock valued at $1,904,000 after buying an additional 7,742 shares during the last quarter. Quarry LP raised its stake in Lantheus by 51.3% during the second quarter. Quarry LP now owns 1,145 shares of the medical equipment provider’s stock worth $92,000 after acquiring an additional 388 shares during the period. Finally, Cetera Investment Advisers lifted its holdings in Lantheus by 34.8% in the second quarter. Cetera Investment Advisers now owns 29,592 shares of the medical equipment provider’s stock worth $2,376,000 after acquiring an additional 7,640 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

LNTH has been the subject of several recent research reports. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Finally, Truist Financial reissued a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Stock Performance

Shares of LNTH stock opened at $91.13 on Wednesday. The firm has a market capitalization of $6.34 billion, a PE ratio of 15.16 and a beta of 0.46. Lantheus Holdings, Inc. has a 1 year low of $51.79 and a 1 year high of $126.89. The stock has a fifty day moving average of $91.78 and a two-hundred day moving average of $100.12.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.